The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome - A case report

Angiology

Volumn 49, Issue 1, 1998, Pages 61-67

  Lewis, Bruce E ^a   Rangel, Yadira ^a   Fareed, Jawed ^b  

^a Diamond Inpatient Headache Unit   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; HEPARIN;

AGED; ANTICOAGULANT THERAPY; ARTERY CATHETERIZATION; ARTICLE; CAROTID ARTERY BRUIT; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY PULSE; CAROTID ARTERY SURGERY; CAROTID ARTERY THROMBOSIS; CASE REPORT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; REVASCULARIZATION; STENT; THROMBOCYTOPENIA;

EID: 0031974853     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979804900108     Document Type: Article

References (27)

1. Kelton JG, Smith IW, Warkentin TE, et al: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-3239, 1994.
2. Greinacher A, Poetzsch B, Amiral J, et al: Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71:247-251, 1994.
3. Visentin GP, Ford SE, Scott JP, et al: Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexes with heparin or heparin bound endothelial cells. J Clin Invest 93:81-88, 1994.
4. Gueinadheu A, Liebenhoff U, Kiefel V, et al: Heparin-associated thrombocytopenia: The effects of various intravenous IgG preparations on antibody mediated plated activation. A possible new indication for high dose IV IgG. Thromb Haemost 71:641-645, 1994.
5. Amiral J, Bridey E, Dreyfus M, et al: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95-96, 1992.
6. Adelman B, Sobel M, Fujimura Y, et al: Heparin-associated thrombocytopenia; observations on the mechanism of platelet aggregation. J Lab Clin Med 113:204-210, 1989.
7. Kelton JG, Sheridan D, Santos A, et al: Heparin-induced thrombocytopenia: Laboratory studies. Blood 72:925-930, 1988.
8. Chong BH, Castaldi PA, Berndt M: Heparin-induced thrombocytopenia: Effects of rabbit IgG and FAB and FC fragments on antibody-heparin-platelet interaction. Thromb Res 55:291-295, 1989.
9. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
10. Walls JT, Curtis JJ, Silver D, et al: Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 108:686-693, 1990.
11. Wallis DE, Lewis BE, Pifarre R, et al: Active surveillance for heparin-induced thrombocytopenia on thromboembolism. Chest 106:1205, 1994.
12. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaron (Org 10172). Thromb Haemost 70:554-561, 1993.
13. King DE, Kelton JG: Heparin-induced thrombocytopenia. Ann Intern Med 100:535-540, 1984.
14. Becker PS, Miller VT: Heparin-induced thrombocytopenia. Stroke 20:1149-1159, 1989.
15. Warkentin, Theodore: Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 10:249-258, 1995.
16. Laster J, Elfrink R, Silver D: Reexposure to heparin of patients with heparin-associated antibodies. J Vase Surg 9:677-682, 1989.
17. Schiele F, Villemenot A, Kramarz P, et al: Use of recombinant Hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 50:20-25, 1995.
18. Chamberlin JR, Lewis B, Leya F, et al: Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 11:511-514, 1995.
19. Matsuo T, Kario K, Chikahira Y, et al: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 82:627-629, 1992.
20. Yadar SS, Roubin GS, Iyer SS, et al: Percutaneous treatment of extracranial carotid atherosclerotic disease with balloon-expandable stent placement. Circulation 8:23, 1995.
21. Shawl FA, Efstratiou A, Hoff S, et al: Combined percutaneous carotid stenting and coronary angioplasty during acute ischémic neurologic and coronary syndromes. Am J Cardiol 77:1109-1112, 1996.
22. Lewis BE, Ferguson JJ, Grassman ED, et al: Successful coronary interventions performed with argatroban in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Inv Cardiol 8(9):410-417, 1996.
23. Hijikata A, Okamoto S: In vivo and in vitro studies of a new series of synthetic thrombin inhibitors (abstract). Thromb Res (suppl) 8:83, 1976.
24. Kikumoto R, Tamao Y, Ohkubo K, et al: Thrombin inhibitors: 2. Amide derivatives on N alpha-substituted L-arginine. J Med Chem 23:830-836, 1980.
25. Okamato S, Hijikata A: Potent inhibition of thrombin by a newly synthesized arginine derivative no. 805. The importance of stereostructures of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101:440-446, 1981.
26. Nagasawg H: Phase one study of synthetic antithrombin agent (MD-805) (abstract). Jpn J Clin Pharmacol Ther 12:359, 1981.
27. Dougherty KG, Marsh KC, Edelman SK, et al: Relationship between procedural activated clotting time and in-hospital post-PTCA outcome (abstract). Circulation 82:III-189, 1990.